Skip to content

Management Team

Renée Aguiar-Lucander

Chief Executive Officer

Renée Aguiar-Lucander

Chief Executive Officer

Born 1962. CEO since 2017.

Education:
BA in Finance from Stockholm School of Economics. MBA from INSEAD.

Experience:
Before joining Calliditas, Renée Aguiar-Lucander was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée Aguiar-Lucander was the European Group Head and Managing Director at a global investment bank and has more than 12 years’ experience in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of software for financial services.

Other current assignments: –

Holdings in the Company:
Renée Aguiar-Lucander holds 643,000 shares in the Company and 591,000 options.

calliditas-frank-bringstrup-people

Frank Bringstrup

Vice President Regulatory Affairs
calliditas-frank-bringstrup-people

Frank Bringstrup

Vice President Regulatory Affairs

Born 1959. VP Regulatory Affairs since 2019.

Education:
Medical education from the University of Copenhagen. He has a diploma in Managing Medical Product Innovation (MMPI) from the Copenhagen School of Economics, a diploma in business administration from Warwick University, and a post graduate specialist course in public health science from the National Board of Health, Denmark.

Experience:
Frank Bringstrup has over 17 years of experience in the pharmaceutical industry within regulatory affairs and health authority interactions. Prior to joining Calliditas, he worked in various positions at Novo Nordisk A / S. He started his professional career first as a clinic doctor and then Frederiksborg County Medical Advisor.

Holding in the Company:
Frank Bringstrup holds 8,000 shares in the Company and 95,000 options.

sandra-frithiof-picture

Sandra Frithiof

Head of Human Resources
sandra-frithiof-picture

Sandra Frithiof

Head of Human Resources

Born 1975. Head of HR since 2020.

Education:
Bachelor’s Degree in Human Resource Management from Örebro University, Sweden.

Experience:
Sandra Frithiof has more than 23 years of HR experience in different industries. Before joining Calliditas Sandra worked as Head of HR and COO at Ramberg Advokater. Previous HR positions also include Karolinska University Hospital, UTC, CGI and Manpower Group.

Holdings in the Company:
Sandra Frithiof holds 75,000 options.

fredrik-johansson-calliditas

Fredrik Johansson

Chief Financial Officer
fredrik-johansson-calliditas

Fredrik Johansson

Chief Financial Officer

Born 1977. CFO since 2017.

Education:
Studies in Business Law at Jönköping International Business School. Studies in Business and American law, Economics and Finance at Georgia State University, University of South Carolina and Lund University.

Experience:
Fredrik Johansson has extensive experience in executive positions, primarily within telecom and software. Previously, he was CFO and COO at Birdstep Technology/ Techstep ASA, listed on the Oslo Stock Exchange, where he, among other things, was in charge of the acquisition and reversed listing of Teki Solutions. Previous CFO positions also include Phone Family, Teligent Telecom and Wayfinder Systems.

Holdings in the Company:
Fredrik Johansson holds 42,750 shares in the Company and 205,000 options.

richard-philipson

Richard Philipson

Chief Medical Officer
richard-philipson

Richard Philipson

Chief Medical Officer

Born 1964. Chief Medical Officer since 2020.

Education:
BSc in Biomedical Sciences at London University and MB MS, Middlesex Hospital Medical School. Fellow of the Royal College of Physicians and Fellow of the Faculty of Pharmaceutical Medicine.

Experience:
Dr. Richard Philipson is a physician with 24 years of experience in the pharmaceutical industry from both large pharmaceutical companies and smaller biotechs. He has extensive experience in rare diseases, having brought several products from early development to the market. Prior to joining Calliditas, Richard worked as CMO with the UK-based biotech company Trizell where he led the Adstiladrin® phase 3 clinical program and Biologics License Application in non-muscle invasive bladder cancer, submitted to the FDA in September 2019. Before Trizell, he worked for Takeda as an Executive Medical Director and spent 16 years at GlaxoSmithKline, where he held a number of senior positions, including Disease Area Head and Acting Chief Medical Officer for the Rare Diseases Unit.

Before joining the industry, Richard worked as a physician in several clinical positions with various patient populations, including patients with IgA nephropathy.

Holdings in the Company: 125,000 options.

Goodwin Headshots, NYC -Jonathan Schur-

Jonathan Schur

Group General Counsel
Goodwin Headshots, NYC -Jonathan Schur-

Jonathan Schur

Group General Counsel

Born 1953. Group General Counsel since 2020.

Education:
Bachelor’s Degree in 1975 from Harvard University, J.D from Harvard Law School.

Experience:
Jonathan Schur has over 40 years of experience as a lawyer, is a member of the New York Bar, and a former member of the Paris Bar. Prior to joining Calliditas, Mr. Schur was a Partner in the Life Sciences practice group at Goodwin Procter LLP, and before that a partner and co-managing partner of the Paris Office of Dechert LLP.

Holdings in the Company:
Jonathan Schur holds 165,000 options.

Andrew Udell

Andrew Udell

President, North America
Andrew Udell

Andrew Udell

President, North America

Born 1970. Head of North America, Commercial since 2020. 

Education:
BSc from Lehigh University. MBA from the University of Connecticut

Experience:
Andrew Udell has more than 20 years of commercial experience in the pharmaceutical industry. Before joining Calliditas, Andrew worked as Vice President of North America Commercial at NeuroDerm. Andrew began his career in the pharmaceutical industry at Purdue Pharma and held several sales and marketing positions, including being responsible for the company’s brands and leading a multi-functional team for a multi-billion pain medication franchise.

Holding in the Company:
Andrew Udell holds 26,000 shares in the company and 235,000 options.

katayoun-welin-berger

Katayoun Welin-Berger

Vice President Operations
katayoun-welin-berger

Katayoun Welin-Berger

Vice President Operations

Born 1968. VP Operations since 2020.

Education:
PhD in Pharmacy from Uppsala University, Sweden.

Experience:
Katayoun Welin-Berger has more than 28 years of commercial experience in the pharmaceutical and biologics industry. Before joining Calliditas, Katayoun worked as Vice President of Operations at BioGaia. Katayoun began her career in the pharmaceutical industry at AstraZeneca and held several positions within both R&D and Operations.

Holding in the Company:
Katayoun Welin-Berger holds 11,000 shares through a related party and 95,000 options.

Shareholding in the Company as of December 31, 2022.

For more information on the warrants, see section Remuneration.